Deal Library / Pharma BD Deal Intelligence
Eli Lilly and Company — Pharma Deals
The Pharma Closeout tracks 101 deals, $131.5B in disclosed deal value, 27 with a post-close Outcome Score for Eli Lilly and Company.
Median Critic Score: 75 · Median Outcome Score: 61
Best outcome: Eli Lilly and Company / Boehringer Ingelheim GmbH (89) · Weakest outcome: Eli Lilly and Company / Alnara Pharmaceuticals (13)
All 101 deals
- Eli Lilly and Company / Boehringer Ingelheim GmbH — 2011 · $444M · Worked — the deal delivered on its rationale.
- Eli Lilly and Company / Loxo Oncology, Inc. — 2019 · $8.0B · Worked — the deal delivered on its rationale.
- Eli Lilly and Company / Applied Molecular Evolution Inc. — 2003 · $400M · Worked — the deal delivered on its rationale.
- Eli Lilly and Company / ICOS Corporation — 2006 · $2.3B · Worked — the deal delivered on its rationale.
- Eli Lilly and Company / Novartis Animal Health — 2014 · $5.4B · Largely worked — most objectives met.
- Eli Lilly and Company / Incyte Corporation — 2009 · $755M · Largely worked — most objectives met.
- Eli Lilly and Company / Hanmi Pharmaceutical Co. Ltd. — 2026 · $1.3B · Largely worked — most objectives met.
- Eli Lilly and Company / Scorpion Therapeutics — 2025 · $2.5B · Largely worked — most objectives met.
- Eli Lilly and Company / Versanis Bio — 2023 · $1.9B · Largely worked — most objectives met.
- Eli Lilly and Company / Ascidian Therapeutics, Inc. — 2026 · $1.9B · Largely worked — most objectives met.
- Eli Lilly and Company / Morphic Holdings — 2024 · $3.2B · Largely worked — most objectives met.
- Eli Lilly and Company / Point Biopharma — 2023 · $1.4B · Largely worked — most objectives met.
- Eli Lilly and Company / AtaiBeckley Inc. — 2026 · $3.8B · Largely worked — most objectives met.
- Eli Lilly and Company / ImClone Systems Incorporated — 2008 · $6.5B · Largely worked — most objectives met.
- Eli Lilly and Company / AC Immune SA — 2017 · $2.0B · Mixed — partial payoff, real shortfalls.
- Eli Lilly and Company / Haisco Pharmaceutical Group Co., Ltd. — 2026 · $3.1B · Mixed — partial payoff, real shortfalls.
- Eli Lilly and Company / CoLucid Pharmaceuticals — 2017 · $960M · Mixed — partial payoff, real shortfalls.
- Eli Lilly and Company / Seamless Therapeutics GmbH — 2026 · $1.1B · Mixed — partial payoff, real shortfalls.
- Eli Lilly and Company / AlzeCure Pharma AB — 2026 · $1.0B · Mixed — partial payoff, real shortfalls.
- Eli Lilly and Company / Sangamo Therapeutics, Inc. — 2026 · $50M · Mixed — partial payoff, real shortfalls.
- Eli Lilly and Company / Avid Radiopharmaceuticals, Inc. — 2010 · $800M · Mixed — partial payoff, real shortfalls.
- Eli Lilly and Company / 4E Therapeutics, Inc. — 2026 · Mixed — partial payoff, real shortfalls.
- Eli Lilly and Company / DICE Therapeutics Inc. — 2023 · $2.4B · Mixed — partial payoff, real shortfalls.
- Eli Lilly and Company / Prevail Therapeutics — 2020 · $1.0B · Mixed — partial payoff, real shortfalls.
- Eli Lilly and Company / Sigilon Therapeutics Inc. — 2018 · $1.8B · Underwhelmed — fell short of the thesis.
- Eli Lilly and Company / ARMO BioSciences Inc. — 2018 · $1.6B · Did not work — the deal failed to deliver.
- Eli Lilly and Company / Alnara Pharmaceuticals — 2010 · $380M · Did not work — the deal failed to deliver.
- Eli Lilly and Company / Repertoire Immune Medicines Inc. — 2026 · $1.9B
- Eli Lilly and Company / Vaccine Company, Inc. — 2026 · $1.6B
- Eli Lilly and Company / Kelonia Therapeutics, Inc. — 2026 · $7.0B
- Eli Lilly and Company / QurCan Therapeutics Inc. — 2026 · $237M
- Eli Lilly and Company / Profluent Bio — 2026 · $2.2B
- Eli Lilly and Company / Innovent Biologics, Inc. — 2026 · $8.8B
- Eli Lilly and Company / Curevo Vaccine, Inc. — 2026 · $1.5B
- Eli Lilly and Company / Insilico Medicine Inc. — 2026 · $2.8B
- Eli Lilly and Company / OmniAb, Inc. — 2026 · $370M
- Eli Lilly and Company / BioArctic AB — 2026 · $800M
- Eli Lilly and Company / LimmaTech Biologics AG — 2026 · $780M
- Eli Lilly and Company / InnoCare Pharma Limited — 2026 · $3.4B
- Eli Lilly and Company / Engage Biologics, Inc. — 2026 · $202M
- Eli Lilly and Company / Merida Biosciences, Inc. — 2026 · $2.9B
- Eli Lilly and Company / Gate Bioscience — 2026 · $870M
- Eli Lilly and Company / Abbisko Therapeutics Co., Ltd. — 2026 · $1.9B
- Eli Lilly and Company / Centessa Pharmaceuticals plc — 2026 · $7.8B
- Eli Lilly and Company / Amplitude Therapeutics, Inc. — 2026
- Eli Lilly and Company / Ajax Therapeutics, Inc. — 2026 · $2.3B
- Eli Lilly and Company / CSL Limited — 2026 · $100M
- Eli Lilly and Company / AC Immune SA — 2026
- Eli Lilly and Company / CrossBridge Bio, Inc. — 2026 · $300M
- Eli Lilly and Company / METiS TechBio — 2026 · $1.1B
- Eli Lilly and Company / Orna Therapeutics, Inc. — 2026 · $2.4B
- Eli Lilly and Company / Ventyx Biosciences, Inc. — 2026 · $1.2B
- Eli Lilly and Company / MeiraGTx — 2025
- Eli Lilly and Company / Magnet Biomedicine — 2025
- Eli Lilly and Company / Organovo Holdings, Inc. — 2025 · $50M
- Eli Lilly and Company / Juvena Therapeutics, Inc. — 2025 · $650M
- Eli Lilly and Company / Camurus AB — 2025 · $870M
- Eli Lilly and Company / Verve Therapeutics, Inc. — 2025 · $1.3B
- Eli Lilly and Company / Rznomics Inc. — 2025
- Eli Lilly and Company / Alchemab Therapeutics — 2025
- Eli Lilly and Company / Adverum Biotechnologies, Inc. — 2025 · $261M
- Eli Lilly and Company / QIAGEN — 2024
- Eli Lilly and Company / Radionetics Oncology Inc. — 2024 · $1.1B
- Eli Lilly and Company / HAYA Therapeutics SA — 2024 · $1.0B
- Eli Lilly and Company / Beam Therapeutics Inc. — 2023 · $600M
- Eli Lilly and Company / PRISM BioLab — 2023
- Eli Lilly and Company / Sigilon Therapeutics Inc. — 2023 · $310M
- Eli Lilly and Company / XtalPi — 2023 · $250M
- Eli Lilly and Company / Mablink Bioscience SAS — 2023 · $250M
- Eli Lilly and Company / Capsida Biotherapeutics — 2023
- Eli Lilly and Company / Abbisko Therapeutics Co., Ltd. — 2022
- Eli Lilly and Company / Nimbus Therapeutics LLC — 2022 · $496M
- Eli Lilly and Company / Entos Pharmaceuticals — 2022
- Eli Lilly and Company / Sosei Group Corp. (Sosei Heptares) — 2022 · $730M
- Eli Lilly and Company / Akouos Inc. — 2022 · $610M
- Eli Lilly and Company / MiNA Therapeutics Limited — 2021
- Eli Lilly and Company / ALX Oncology — 2021
- Eli Lilly and Company / Protomer Technologies — 2021 · $1.0B
- Eli Lilly and Company / Foghorn Therapeutics Inc. — 2021 · $1.7B
- Eli Lilly and Company / Regor Therapeutics Group — 2021
- Eli Lilly and Company / Kumquat Biosciences, Inc. — 2021 · $2.1B
- Eli Lilly and Company / Lycia Therapeutics, Inc. — 2021
- Eli Lilly and Company / Blacksmith Medicines, Inc. — 2021 · $300M
- Eli Lilly and Company / Rigel Pharmaceuticals, Inc. — 2021 · $960M
- Eli Lilly and Company / Asahi Kasei Pharma — 2021 · $230M
- Eli Lilly and Company / Merus N.V. — 2021 · $1.7B
- Eli Lilly and Company / Precision BioSciences, Inc. — 2020
- Eli Lilly and Company / Dermira Inc. — 2020 · $1.1B
- Eli Lilly and Company / Sermonix Pharmaceuticals Inc. — 2020
- Eli Lilly and Company / Seed Therapeutics — 2020
- Eli Lilly and Company / Evox Therapeutics Ltd — 2020
- Eli Lilly and Company / Shanghai Junshi Biosciences Co., Ltd. — 2020 · $255M
- Eli Lilly and Company / Disarm Therapeutics — 2020
- Eli Lilly and Company / AC Immune SA — 2019 · $1.9B
- Eli Lilly and Company / AurKa Pharma Inc. — 2019 · $575M
- Eli Lilly and Company / Centrexion Therapeutics Corporation — 2019 · $575M
- Eli Lilly and Company / ImmuNext Inc. (anti-VISTA license) — 2019 · $350M
- Eli Lilly and Company / Hanmi Pharmaceutical Co., Ltd. (HM71224 program) — 2015 · $690M
- Eli Lilly and Company / Immunocore Limited — 2014 · $365M
- Eli Lilly and Company / Adocia SA — 2014 · $570M
- Eli Lilly and Company / Acrux Limited (AXIRON license) — 2010 · $335M
← Deal Library ·
Interactive search ·
How we score deals